Form 4: AIM ImmunoTech CEO Thomas Equels Increases Stake in Company
SEC Form 4 Filing
AIM ImmunoTech CEO Thomas K. Equels purchased 20,000 shares of common stock at a price of $0.212 per share on November 21, 2024.
Summary
- On November 21, 2024, Thomas K. Equels, CEO and President of AIM ImmunoTech Inc., acquired 20,000 shares of the company's common stock.
- The shares were purchased at a price of $0.212 per share.
- Following the transaction, Equels directly owns 1,657,968 shares of AIM ImmunoTech Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed favorably, but the purchase is relatively small and may not be highly significant.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's management believes the stock is undervalued.
Stakeholder Impact
- The purchase could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 11/21/2024 | Date of transaction: Thomas K. Equels purchased 20,000 shares of AIM ImmunoTech Inc. |
| 01/21/2025 | Signature date of the report. |
Keywords
AIM ImmunoTech, insider trading, Form 4, share purchase, Thomas Equels, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.